MaxCyte

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MaxCyte reports robust Q4 earnings, poised for strategic growth

MaxCyte delivered impressive financial results in Q4 2022, showcasing strong revenue growth and a solid core business performance.
Despite facing challenges such as regulatory risks and industry dynamics, the company's strategic strengths and opportunities position it for continued success.
By maintaining a focus on innovation, partnership expansion, and financial prudence, MaxCyte aims to drive growth and navigate industry complexities effectively.

MaxCyte reports revenue decline but eyes growth through strategic partnerships

MaxCyte faced revenue declines in Q1 2023 due to industry challenges but remains positive about its future prospects and partnerships.
Despite financial setbacks, the company is focused on growth opportunities through new partnerships and potential product approvals.
Strategic guidance aims for revenue growth in 2023 and a healthy year-end cash position, signaling stability and long-term planning.

MaxCyte reports Q2 revenue decline but anticipates product approvals

MaxCyte faces revenue challenges but maintains confidence in its outlook with a strong partnership pipeline. The company's financials show a healthy gross margin and a focus on R&D for future growth. Anticipation surrounds the first commercial approval of products enabled by its platform.

MaxCyte meets Q3 revenue targets, eyes FDA milestone payments

MaxCyte's Q3 performance met expectations, with a focus on overcoming challenges in core business areas. The company's strengths lie in its optimism about non-viral engineered cell therapy trends and strong financial position.
While facing challenges in PA sales and operating expenses, MaxCyte sees opportunities in FDA approval milestones, revenue potential from SPL programs, and long-term growth through partnerships and industry support.

MaxCyte reports 2023 revenue decline but strong FDA approval growth

MaxCyte's 2023 performance saw revenue decline but significant achievements with FDA approval for CASGEVY and SPL client growth.
Despite challenges in core revenue, the company's strong financial position and robust SPL portfolio offer growth opportunities.
Guidance for 2024 indicates improved trends with flat to 5% growth, emphasizing the potential in SPL partnerships and financial stability.
Stabilization in funding and patient adoption present opportunities for revenue growth and market expansion in the cell therapy sector.

MaxCyte exceeds Q1 revenue expectations, poised for strategic growth

MaxCyte delivered strong Q1 2024 results, surpassing revenue expectations and demonstrating robust financial performance. With a focus on managing expenses and driving growth, the company is well-positioned to capitalize on its competitive strengths and market opportunities. Challenges lie in sustaining revenue growth and balancing expenses with expansion.

MaxCyte reports robust Q2 revenue, eyes cell therapy growth

MaxCyte's Q2 2024 performance showed solid revenue growth and a strong gross margin. The company's focus on cell therapy innovation and strategic partnerships positions it well for future growth.

MaxCyte exceeds revenue expectations, poised for sustainable growth

MaxCyte's Q3 2024 performance reflects robust revenue growth and strategic investments for long-term success.
While facing challenges like margin impact and cost management, the company's strengths in partnerships and leadership drive opportunities for expansion.
With increased revenue guidance and a disciplined spend approach, MaxCyte is poised for sustained growth and profitability.
Overall, MaxCyte's focus on core revenue, strategic partnerships, and leadership development sets a strong foundation for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intima Bioscience to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates Intima Bioscience to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

GAITHERSBURG, Md., Jan. 23, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today provides a preliminary update on revenue results for the fourth quarter and full year 2021.

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

MaxCyte, Inc. (MXCT) CEO Douglas Doerfler Q3 2021 Results - Earnings Call Transcript

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced third quarter ended September 30, 2021 financial results.

MaxCyte Reports Third Quarter Financial Results

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. The company today announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board. Richard Douglas has been a Board Member since February 2018. He succeeds J. Stark Thompson, PhD, who previously announced his decision not to seek re-election. Dr. Thompson will remain as a consultant to MaxCyte.

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

Nkarta to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates Nkarta to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it is set to join the Russell 3000® and Russell 2000® indices, effective after the U.S. market opens on September 20, 2021, according to a preliminary list of quarterly IPO additions posted earlier this month by FTSE Russell.

MaxCyte Set to Join Russell 2000® Index

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q2 2021 Results - Earnings Call Transcript

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced its financial results for its second quarter and six months ended June 30, 2021.

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100% gross margins) are set to account for a larger percentage of revenues over time.

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

Palo Alto Networks

Victoria's Secret & Co

Bilibili

Omega Therapeutics

Ranpak Holdings Corp

With the trading day more than halfway over, the broad markets were seeing another round of gains on Tuesday.

Tuesday Afternoon Analyst Upgrades and Downgrades: Palo Alto Networks, Victoria's Secret and More

MaxCyte Inc headed 5.8% higher to 1,100p after it granted a pile of options over 100,000 shares (in aggregate) to directors and officers of the company. The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of US$16.63.

MaxCyte grants options after announcing licensing deal yesterday

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

MaxCyte Inc (NASDAQ: MXCT) is already trading on London's AIM, but now, it debuted on NASDAQ after pricing a $176 million IPO at $13 apiece, on the higher end of an $11.50 to $13.50 range. The Company offered 13.5 million shares during the IPO.

London-Listed MaxCyte Makes NASDAQ Debut Today

NEW YORK, July 30, 2021 /PRNewswire/ -- DLA Piper represented Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C., as underwriters in the initial US public offering of 13,500,000 shares of common stock of MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, at an initial offering price of US$13.00 per share.

DLA Piper advises underwriters of MaxCyte's upsized US IPO

Top 10 global pharma companies and 20 of the top 25 revenue earners utilize MaxCyte's cell engineering platform for drug discovery. The Company's clinical license deals have potential pre-commercial milestones totaling more than $950 million.

MaxCyte: Leading Provider Of Cell-Engineering Platform Technologies

GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share (the "Offering").

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market

MaxCyte Inc. has set terms for its initial public offering, in which the Maryland-based cell engineering company could be valued at up to $1.31 billion. The company is looking to raise up to $162.0 million, as it is offering 12.0 million shares in the IPO, which is expected to price between $11.50 and $13.50 a share.

MaxCyte could be valued at more than $1.3 billion as IPO terms have been set

GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering, today announced the public filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed dual listing of its shares of common stock on the Nasdaq Global Market ("Nasdaq") under the symbol "MXCT.

News for MaxCyte Stock (MXCT)